Cardiometabolic disease, in manifestations including atherosclerotic cardiovascular disease (ASCVD), affects millions of Americans in evolved forms of the disease.
Whereas the traditional mean ASCVD patient decades ago was generally male, older aged, with a smoking habit and slight obesity—the contemporary ASCVD patient is a greater mix of females, significantly younger, less likely with a smoking habit and more likely with obesity. They are hyperinsulemic, and present with mixed dyslipidemia.
Particularly when considering that last point: how is the average patient now monitored and treated for cardiometabolic disease risk? With an evolution and growth of risks, there must be a modernization of treatment strategy.
In this special presentation to HCPLive, cardiologist Brett Nowlan, MD, FACC, explains the complexities of cardiometabolic risk evaluation, and how it influences care.
In his talk, Nowlan discusses the interpretation of cardiometabolic risk through 3 factors:
Throughout the presentation, Nowlan highlights the clinical interpretations and biochemistry roles of LDL-P and Apo-B among modern patients with mixed dyslipidemia.
Nowlan also highlights a pair of successful cases treated through a response from panel results, and provides guidance to prescribing clinicians on the utility and priority of panels.